NASDAQ: ABUSArbutus Biopharma Corp Stock Ownership - Who owns Arbutus Biopharma?
Insider buying vs selling
Have Arbutus Biopharma Corp insiders been buying or selling?
No trades
There has been no insiders buying vs selling in the past 12 months.
Be the first to know when ABUS insiders and whales buy or sell their stock.
ABUS Shareholders
What type of owners hold Arbutus Biopharma Corp stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Roivant Sciences Ltd | 19.67% | 38,847,462 | $193.07M | Insider |
| Matthew Gline | 19.67% | 38,847,462 | $193.07M | Insider |
| Dexxon Holdings Ltd | 16.21% | 32,027,080 | $159.17M | Insider |
| Morgan Stanley | 13.11% | 25,891,480 | $128.68M | Institution |
| Two Seas Capital LP | 9.39% | 18,557,543 | $92.23M | Institution |
| Vivek Ramaswamy | 8.13% | 16,068,455 | $79.86M | Insider |
| Patrick MacHado | 8.11% | 16,013,540 | $79.59M | Insider |
| Svf Investments Uk Ltd | 8.11% | 16,013,540 | $79.59M | Insider |
| Dexcel Pharma Technologies Ltd | 8.11% | 16,013,540 | $79.59M | Insider |
| Rose Sharon Shabet | 8.11% | 16,013,540 | $79.59M | Insider |
ABUS vs Biotech Stocks
Arbutus Biopharma Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.